drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Autologous TCR-engineered T-cell (TCR-T) therapy in which patient T cells are genetically modified to express an HLA-A*11:01–restricted, HBV-specific T-cell receptor targeting HBV antigen–expressing hepatocellular carcinoma cells; induces TCR signaling, cytokine release, and MHC class I–restricted cytotoxic killing. Administered with step-up induction followed by weekly maintenance infusions.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Genetically Modified
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an HLA-A*11:01-restricted, HBV-specific T-cell receptor that recognizes HBV peptide–MHC class I complexes on hepatocellular carcinoma cells, activating TCR signaling, cytokine release, and perforin/granzyme-mediated cytotoxic killing.
drug_name
QY-1-T
nct_id_drug_ref
NCT06251115